Corrin Wohlhieter

Corrin Wohlhieter

Auto-generated profile, based on publicly available information

Corrin Wohlhieter

Memorial Sloan Kettering Cancer Center 13 Molecular Pharmacology Program New York, New York

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2026 in Cancer Discovery
Verified
Journal Article
Open access
RPRay Pillai
Ray Pillai
ARAli Rashidfarrokhi
Ali Rashidfarrokhi
YHYuan Hao
Yuan Hao
WWWarren L. Wu
Warren L. Wu
MMMariana C.S. Mancini
Mariana C.S. Mancini
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
LKB1 mutations in lung cancer promote an immunosuppressive tumor microenvironment, but the underlying mechanisms remain unknown. Using genetically engineered mouse models and human tumor samples, we demonstrate that LKB1 loss leads to high expression of the cytokine leukemia-inhibitory factor (LIF), which through a cancer cell–autonomous autocrine loop, orchestrates the infiltration of immunosuppressive SiglecFHi neutrophils and Arg1+ interstitial macrophages. Genetic deletion of Lifr, the receptor for LIF, on Lkb1-mutant lung tumors revealed that autocrine LIF signaling induces tumor plasticity and the emergence of a Sox17+ dedifferentiated inflammatory cell state. Antibody-mediated LIF neutralization selectively eliminates the Sox17+ tumor cell state, reduces immunosuppressive myeloid cells, and enhances antitumor T-cell responses. Our study uncovers a novel LKB1–LIF axis driving immune evasion and identifies LIF as a potential therapeutic target in LKB1-mutant lung cancer. This work highlights the interplay between tumor genetics, cellular plasticity, and immune regulation in lung cancer progression. Significance: LKB1-mutant lung cancers express LIF, which induces an immunosuppressive Sox17+ tumor state. Anti-LIF therapy eliminates this state and restores antitumor immunity, revealing a novel vulnerability in this aggressive cancer subtype lacking effective targeted therapies.

1 July 2026
Verified
Other
Open access
RPRay Pillai
Ray Pillai
ARAli Rashidfarrokhi
Ali Rashidfarrokhi
YHYuan Hao
Yuan Hao
WWWarren L. Wu
Warren L. Wu
MMMariana C.S. Mancini
Mariana C.S. Mancini
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
Identifying the impact of autocrine LIF signaling on myeloid cells.


1 July 2026
Verified
Other
Open access
RPRay Pillai
Ray Pillai
ARAli Rashidfarrokhi
Ali Rashidfarrokhi
YHYuan Hao
Yuan Hao
WWWarren L. Wu
Warren L. Wu
MMMariana C.S. Mancini
Mariana C.S. Mancini
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
Immune analysis of human LKB1 mutant lung tumors.

1 July 2026
Verified
Other
Open access
RPRay Pillai
Ray Pillai
ARAli Rashidfarrokhi
Ali Rashidfarrokhi
YHYuan Hao
Yuan Hao
WWWarren L. Wu
Warren L. Wu
MMMariana C.S. Mancini
Mariana C.S. Mancini
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
LIF neutralization eliminates a dedifferentiated stem-like tumor cell state.

1 July 2026
Verified
Other
Open access
PDF file
RPRay Pillai
Ray Pillai
ARAli Rashidfarrokhi
Ali Rashidfarrokhi
YHYuan Hao
Yuan Hao
WWWarren L. Wu
Warren L. Wu
MMMariana C.S. Mancini
Mariana C.S. Mancini
TPThales Papagiannakopoulos
Thales Papagiannakopoulos
Gating strategy for immune cells.